Please Wait
Applying Filters...
menu
    • menu
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    Inebilizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    26/09/2024 AstraZeneca
    United Kingdom
    		 AstraZeneca Pharmaceuticals LP 302MF40018 Culture medium/Culture additives - Inebilizumab Media 2020-06-04 2020-06-04 One MedImmune Way, Gaithersburg, MD 20878, USA
    26/09/2024 AstraZeneca
    United Kingdom
    		 AstraZeneca Pharmaceuticals LP 303MF40004 Media/Media Additives - Inebelizumab Production Media 2021-01-26 2021-01-26 One MedImmune Way, Gaithersburg, MD 20878, USA